Skip to main content
profileAnalyst coverage5 yr. financialspremium researchdividendsadv. chartsearningsoptionsprice history

Advaxis, Inc. News

SeaSpine Lauded by Analysts After Spine Module Cleared by FDA

The Food and Drug Administration’s cleared SeaSpine's 7D Percutaneous Spine Module for spinal surgery. The company's shares are higher.

Biohaven Leaps After Posting $93M Sales for Migraine Drug

Biohaven's Nurtec was approved for migraine treatment in February 2020 and for prevention this past May. Q2 sales: $93 million.

Advaxis Jumps on Deal to Be Bought by Biosight

Advaxis shares advanced after the company agreed to be purchased by peer biotech Biosight of Israel.

Small Caps Continue to Outperform on Tax Reform, Oil Marches Higher - ICYMI

Here's what you need to know now for Wednesday, Sept. 27.

Biotech Movers: Array Shares Rise on Bristol-Myers Collaboration

Array BioPharma, Advaxis, Merrimack Pharmaceuticals and Insys Therapeutics were among the biotech stock movers in premarket trading on Tuesday.

Breaking News

Elon Musk Throws Dogecoin a Lifeline

Elon Musk will soon allow Dogecoin to purchase SpaceX merchandise.

Disney Fans Angry, Excited About New Guardians of the Galaxy Ride

The theme park company has opened Guardians of the Galaxy: Cosmic Rewind and not everyone is happy despite the ride getting wonderful reviews.

Aurora Cannabis Slashing Weed Capacity in Profitability Push

Aurora is slashing its production capacity as it builds a runway toward positive Ebitda a year from now.

Costco Beats Q3 Sales Forecast, Membership Revenues Near $1 Billion

Costco took in $984 million in new membership fee in its fiscal third quarter, helping the bulk retailer top Street forecasts for topline revenues.